XML 42 R27.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurements
12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
 
Liabilities Measured at Fair Value on a Recurring Basis
 
The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2016:
 
(in thousands)
Level 1
Level 2
Level 3
Total
Warrant consideration(1)
$

$
1,080

$

$
1,080

Tax amortization benefit contingency(2)


150,260

150,260

Deferred acquisition payment(3)


2,498

2,498

Stock appreciation rights(4)


22

22

Phantom shares(5)


4

4

Total
$

$
1,080

$
152,784

$
153,864


The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2015:

(in thousands)
Level 1
Level 2
Level 3
Total
Warrant consideration(1)
$

$
6,000

$

$
6,000

Tax amortization benefit contingency(2)


149,620

149,620

Deferred acquisition payment(3)


22,700

22,700

Stock appreciation rights(4)


27

27

Phantom shares(5)


20

20

Total
$

$
6,000

$
172,367

$
178,367


———————————————————————————————
(1)      
This liability relates to warrants to purchase the Company's common stock and future obligations to deliver additional warrants in relation to the Business Combination. The inputs used in the fair value measurement were directly observable quoted prices for identical assets in an inactive market.
(2)    
The fair value of the tax amortization benefit contingency is measured using an income approach based on the Company’s best estimate of the undiscounted cash payments to be made, tax effected at 37% and discounted to present value utilizing an appropriate market discount rate. The valuation technique used did not change during the five months ended December 31, 2015 or during the twelve months ended December 31, 2016.
(3)   
The fair value of the deferred acquisition payment is measured using a Black-Scholes option pricing model and based on the Company’s best estimate of the Company’s average Business EBITDA, as defined in the Purchase Agreement, over the two year period from January 1, 2016 to December 31, 2017. The valuation technique used did not change during the five months ended December 31, 2015 or during the twelve months ended December 31, 2016.
(4)
The fair value of the stock appreciation right was measured using a Hull-White option pricing mode during the five months ended December 31, 2015 and a Black Scholes pricing model during the twelve months ended December 31, 2016.
(5)
The fair value of phantom shares are based on the fair value of the Company's common stock. The valuation technique used did not change during the five months ended December 31, 2015 or the twelve months ended December 31, 2016.
 
There were no transfers between Level 1 and Level 2 and no transfers out of Level 3 of the fair value hierarchy during the twelve months ended December 31, 2016 and the five months ended December 31, 2015.
 
At December 31, 2016, the Company evaluated the amount recorded under the Term Loan and determined that the fair value was approximately $380.9 million. At December 31, 2015, the carrying value of the Term Loan approximated the fair value. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.
 
Changes in Financial Instruments Measured at Level 3 Fair Value on a Recurring Basis
 
The following tables present the changes during the periods presented in our Level 3 financial instruments that are measured at fair value on a recurring basis. These instruments relate to contingent consideration payable to Dow in relation to the Business Combination.
 
(in thousands)
Tax amortization
benefit contingency
Deferred
acquisition payment
Stock appreciation rights
Phantom shares
Total
Balance, December 31, 2015
$
149,620

$
22,700

$
27

$
20

$
172,367

Measurement period adjustment
2,223

(2,000
)


223

Accretion
15,859

14,338



30,197

Stock compensation expense





Mark-to-market adjustment
(17,442
)
(32,540
)
(5
)
(16
)
(50,003
)
Balance, December 31, 2016
$
150,260

$
2,498

$
22

$
4

$
152,784